Recent Understanding and Future Directions in the Application of MMP-2 in Encapsulating Peritoneal Sclerosis Clinical

Yaxuan Fang1,2, Xin Chen1,2, Ke Zhong1,2

  • 1Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Blood Purification
|January 4, 2023
PubMed

Insights

Matrix metalloproteinase-2 (MMP-2) may serve as a novel biomarker for detecting Encapsulating Peritoneal Sclerosis (EPS). This review explores MMP-2

Area of Science:

  • Nephrology
  • Gastroenterology
  • Biochemistry

Background:

  • Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis.
  • Extracellular matrix remodeling is implicated in EPS pathogenesis.
  • Matrix metalloproteinase-2 (MMP-2) is a key protease involved in matrix degradation.

Purpose of the Study:

  • To review the role of MMP-2 in the etiologies of EPS.
  • To assess the clinical application value of MMP-2 as a biomarker for EPS detection.
  • To highlight future research directions for MMP-2 in EPS.

Main Methods:

  • Literature review of studies investigating MMP-2 and EPS.
  • Analysis of MMP-2's involvement in various EPS causes.
  • Evaluation of MMP-2's diagnostic potential.

Main Results:

  • MMP-2 plays a significant role in the extracellular matrix changes associated with EPS.
  • Elevated MMP-2 levels are observed in EPS patients.
  • MMP-2 shows promise as a biomarker for early EPS detection.

Conclusions:

  • MMP-2 is a potential biomarker for improving the diagnosis of Encapsulating Peritoneal Sclerosis.
  • Further research is warranted to fully establish MMP-2's clinical utility in managing EPS.